Страна: Канада
мова: англійська
Джерело: Health Canada
BETAMETHASONE (BETAMETHASONE DIPROPIONATE)
ORGANON CANADA INC.
D07AC01
BETAMETHASONE
0.05%
CREAM
BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05%
TOPICAL
15G/50G
Prescription
ANTI-INFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0106299002; AHFS:
APPROVED
2011-02-08
1 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION DIPROSONE ® BETAMETHASONE DIPROPIONATE CREAM, ORGANON STANDARD, 0.05% W/W BETAMETHASONE (AS DIPROPIONATE) BETAMETHASONE DIPROPIONATE OINTMENT, ORGANON STANDARD, 0.05% W/W BETAMETHASONE (AS DIPROPIONATE) BETAMETHASONE DIPROPIONATE LOTION, USP, 0.05% W/W BETAMETHASONE (AS DIPROPIONATE) Topical Corticosteroid ORGANON CANADA INC. 16766 route Transcanadienne Kirkland, Quebec H9H 4M7 www.organon.ca Date of Initial Approval: NOV 07, 1974 Date of Revision: April 7, 2021 Submission Control No.: 249884 2 TABLE OF CONTENTS TABLE OF CONTENTS ..............................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 1 INDICATIONS ..................................................................................................................3 1.1 Pediatrics ....................................................................................................................3 1.2 Geriatrics ....................................................................................................................3 2 CONTRAINDICATIONS .................................................................................................3 3 DOSAGE AND ADMINISTRATION .............................................................................3 3.1 Dosing Considerations ...............................................................................................3 3.2 Administration ...........................................................................................................4 4 MISSED DOSE ..................................................................................................................4 5 OVERDOSAGE .................................................................................................................4 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ................4 7 WARNINGS AND PRECAUTIONS ......... Прочитайте повний документ